Veerhealth Care Q1 FY27: Revenue up 456% YoY, PAT at Rs 122.66 lakh

Revenue growth above 20%Profit growth above 25%Related-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹46.95

prior close

₹48.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.3% vs market

Pharmaceuticals peers, median of 166sector-0.4%+0.2% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-2.7

15m

-1.6

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.1-0.3-0.4+0.2

Next day

+4.2+0.2+4.0-0.5+4.6

+2.3+0.6+1.7-0.6+2.8

+1.2-0.0+1.2-1.4+2.6

+4.3+0.5+3.8-0.9+5.2

+4.4+0.8+3.6-0.4+4.8

+2.0+0.6+1.4-0.9+2.9

15d

+5.4+1.3+4.2+0.0+5.4

+8.6-1.4+9.9-0.1+8.7

+5.8-0.6+6.4-2.8+8.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Veerhealth Care posted strong Q1 FY27 results with revenue from operations at Rs 2,492.56 lakh versus Rs 448.52 lakh in Q1 FY26, nearly 5x growth. Profit after tax rose to Rs 122.66 lakh from Rs 24.06 lakh, with EPS of Rs 0.61 versus Rs 0.12. Board approved 1 crore convertible warrants at Rs 20.25 each, with Rs 487.25 lakh already received. Company Secretary Ashita Chittora resigned; Ruchi Shah, daughter of Chairman Yogesh Shah, appointed as replacement. 34th AGM set for September 23, 2026.

Likely market impact

Strong revenue and profit growth signal business momentum. Related-party appointment of new CS may draw governance attention from investors.